The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm (41) and rrl Sequencing
Open accessAbstract
Clarithromycin was the drug of choice for Mycobacterium abscessus infections until inducible resistance due to erm (41) was described. Because M. abscessus was split into M. abscessus sensu stricto, Mycobacterium massiliense , and Mycobacterium bolletii , we looked for erm (41) in the three species and determined their clarithromycin susceptibility levels. Ninety strains were included: 87 clinical strains from cystic fibrosis patients (61%) and others (39%), representing 43 M. abscessus , 30 M. massiliense , and 14 M. bolletii strains identified on a molecular basis, and 3 reference strains. Clarithromycin and azithromycin MICs were determined by broth microdilution and Etest with a 14-day incubation period. Mutations in rrl (23S rRNA gene) known to confer acquired clarithromycin resistance were also sought. erm (41) was detected in all strains but with two deletions in all M. massiliense strains. These strains were indeed susceptible to clarithromycin (MIC 90 of 1 μg/ml) except for four strains with rrl mutations. M. abscessus strains harbored an intact erm (41) but had a T/C polymorphism at the 28th nucleotide: T28 strains (Trp10 codon) demonstrated inducible clarithromycin resistance (MIC 90 of >16 μg/ml), while C28 strains (Arg10) were susceptible (MIC 90 of 2 μg/ml) except for two strains with rrl mutations. M. bolletii strains had erm (41) sequences similar to the sequence of the T28 M. abscessus group, associated with inducible clarithromycin resistance (MIC 90 of >16 μg/ml). erm (41) sequences appeared species specific within the M. abscessus group and were fully concordant with clarithromycin susceptibility when erm (41) sequencing was associated with detection of rrl mutations. Clarithromycin-resistant strains, including the six rrl mutants, were more often isolated in cystic fibrosis patients, but this was not significantly associated with a previous treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes
Woods, G. L., Brown‐Elliott, B. A., Conville, P. S., Desmond, E. P., Hall, G. S., Lin, G., Pfyffer, G. E., Ridderhof, J. C., Siddiqi, S. H., Wallace, R. J., et al. (2011) · Cited by 1,136
Nontuberculous mycobacteria and associated diseases.
Oatway, J. W. H. (1979) · PubMed · doi:10.1164/arrd.1979.120.6.1389 · Cited by 992
Brown-Elliott, B. A., & Wallace, R. J. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.4.716-746.2002 · Cited by 909
Nash, K. A., Brown-Elliott, B. A., & Wallace, R. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01275-08 · Cited by 638
Griffith, D. E., Girard, W. M., & Wallace, R. J. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/147.5.1271 · Cited by 518
Kirschner, P., Springer, B., Vogel, U., Meier, A., Wrede, A., Kiekenbeck, M., Bange, F. C., & Böttger, E. C. (1993) · Journal of Clinical Microbiology · doi:10.1128/jcm.31.11.2882-2889.1993 · Cited by 479
Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis
Esther, C. R., Esserman, D. A., Gilligan, P., Kerr, A., & Noone, P. G. (2010) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.12.001 · Cited by 410
Non Mycobacterial Virulence Genes in the Genome of the Emerging Pathogen Mycobacterium abscessus
Ripoll, F., Pasek, S., Schenowitz, C., Dossat, C., Barbe, V., Rottman, M., Macheras, E., Heym, B., Herrmann, J.-L., Daffé, M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005660 · Cited by 388
Self-citation
Cited by
Daley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00535-2020 · Cited by 924
Self-citationDaley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa241 · Cited by 890
Self-citationNon-tuberculous mycobacteria and the rise of Mycobacterium abscessus
Johansen, M. D., Herrmann, J.-L., & Kremer, L. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0331-1 · Cited by 822
Mycobacterium abscessus: a new antibiotic nightmare
Nessar, R., Cambau, E., Reyrat, J. M., Murray, A., & Gicquel, B. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr578 · Cited by 799
Self-citationDaley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1125 · Cited by 786
Self-citation
Metadata
- Authors
- Bastian, S., Veziris, N., Roux, A.-L., Brossier, F., Gaillard, J.-L., Jarlier, V., & Cambau, E.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-02
- Volume
- 55
- Issue
- 2
- Pages
- 775-781
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2145922409
- Cited by
- 333
- References
- 40
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm (41) and rrl Sequencing. https://app.cochat.ai/papers/10.1128/aac.00861-10
- The paper
- Bastian, S., Veziris, N., Roux, A.-L., Brossier, F., Gaillard, J.-L., Jarlier, V., & Cambau, E. (2011). Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm (41) and rrl Sequencing. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00861-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.